Search Results

You are looking at 131 - 140 of 370 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

a phase II randomized trial for patients with lung cancer. The study is titled TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing

Full access

and risks and discuss them thoroughly with their physician.” Dr. Morgan discussed 2 additional phase III trials assessing bevacizumab (Avastin, Genentech/Roche) combined with carboplatin/paclitaxel in the upfront setting compared with carboplatin

Full access

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu

efficacy of chemotherapy + cetuximab (Cet) or panitumumab (Pani) versus chemotherapy ± bevacizumab (Bev) reported significant improvement in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with chemotherapy + Cet

Full access

A. Scott Paulson and Emily K. Bergsland

strategy remains controversial, and is typically reserved for patients with SSTa-resistant disease. 11 , 14 , 29 Notably, treatment with interferon is the control arm for an ongoing randomized phase III study exploring the use of bevacizumab in patients on

Full access

Daniel Y. C. Heng and Toni K. Choueiri

; 356 : 125 – 134 . 16 Escudier B Koralewski P Pluzanska A . A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar

least 6 weeks, or confirmed partial response or complete response using RECIST was 64%. The median OS was 27 months. 27 Other Therapies for Patients With Non-Clear Cell Carcinomas Bevacizumab is a humanized monoclonal antibody that binds and

Full access

Stefan W. Krause, Jan Schildmann, Christian Lotze, and Eva C. Winkler

given examples of treatments withheld on the grounds of unconvincing evidence and based on an unfavorable cost/benefit analysis were erlotinib, bevacizumab, and other antibodies ( Table 3 , Q5 and Q7). Typical examples for withholding treatments because

Full access

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

as bevacizumab, sorafenib, or sunitinib, could complement the downstream antiangiogenic effect of mTOR inhibition. Various tyrosine kinase inhibitors could interrupt the activation of various upstream mTOR signaling pathways, thus complementing direct

Full access

Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna

these agents, novel therapies or combinations are needed. A recent phase II study met its primary endpoint by showing improved progression-free survival with the combination of TAS-102/bevacizumab compared with TAS-102 alone in patients with refractory

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory

. 118 , 119 Targeted Therapies: Specific targeted therapies have been developed for the treatment of advanced lung cancer. 120 , 121 Bevacizumab is a recombinant monoclonal antibody that blocks the vascular endothelial growth factor (VEGF). Erlotinib